Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 4Thoracic 3Sarcoma 3Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DOXO-EMCH × Gastrointestinal × Clear all
NCT01580397 2024-06-06

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Completed
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡